Capstone reaffirms FY2026 revenue outlook at $72.1 million, EBITDA at $3.8 million

Capstone Holding Corp

Capstone Holding Corp

CAPS

0.00
  • Capstone Therapeutics reaffirmed FY2026 guidance for revenue of $72.1 million, up 54%, with gross profit of about $18.7 million, up 73%.
  • Outlook also calls for EBITDA of about $3.8 million, implying roughly 322% year-over-year growth, with a positive EBITDA run-rate expected from Q2.
  • Guidance follows progress on capital structure, with about 72% of $6.82 million original convertible-note principal converted as of May 1, leaving $1.9 million outstanding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-015014), on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.